Mayo Shows Cybor-D More Effective for Multiple Myeloma
A phase II trial conducted by researchers from the Mayo Clinic and Prince Margaret Hospital shows a new drug regimen is more effective than traditional treatments in helping newly-diagnosed patients with multiple myeloma.
The new treatment, known as Cybor-D, consists of cyclophosphamide, bortezomib and dexamethasone. To arrive at their findings, the team administered the investigational Cybor-D treatments to 30 patients while 34 other patients received standard L-Dex treatments consisting of lenalidomide-dexamethasone.
Their study revealed newly-diagnosed multiple myeloma patients receiving Cybor-D treatments responded better than those receiving L-Dex therapy. In a majority of cases, Cybor-D recipients experienced a rapid reduction in M protein antibodies which can build up in bone marrow, thicken blood, or cause kidney damage.
Dr Craig B Reeder presented the group’s findings at the American Society of Hematology’s annual meeting in Atlanta, Georgia, held December 8-11, 2007.
Source: Mayo Foundation for Medical Education and Research
Related Links: Bio-medicine.org; American Cancer Society; labtestsonline.org
Related Podcast: Multiple Myeloma: How to Treat Patients that Progress or Relapse from the National Comprehensive Cancer Network
Tags: blood cancers; Mayo Clinic Cancer Center; Toronto; oncology; chemotherapy; hematologic malignancies
Print This
|
| Sphere: Related Content
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URI
Leave a comment
Browse All Categories: Next article: Diabetic Women Have Higher Risk of Colorectal Cancer
Previous article: Technetium-99 Shortage Delays Cancer Tests
